{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T08:20:48Z","timestamp":1782894048598,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T00:00:00Z","timestamp":1535328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T00:00:00Z","timestamp":1535328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s12185-018-2517-0","type":"journal-article","created":{"date-parts":[[2018,8,27]],"date-time":"2018-08-27T14:45:55Z","timestamp":1535381155000},"page":"588-597","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper\/cytotoxic CD4 T cells in chronic myelogenous leukemia patients"],"prefix":"10.1007","volume":"108","author":[{"given":"Naoki","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoiku","family":"Takaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyoshi","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Shirane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuko","family":"Toyota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,27]]},"reference":[{"key":"2517_CR1","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872\u201384.","journal-title":"Blood"},{"key":"2517_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917\u201327.","journal-title":"N Engl J Med"},{"key":"2517_CR3","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.clinthera.2007.11.005","volume":"29","author":"M Steinberg","year":"2007","unstructured":"Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther. 2007;29:2289\u2013308.","journal-title":"Clin Ther"},{"key":"2517_CR4","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. 2016;30:1044\u201354.","journal-title":"Leukemia"},{"key":"2517_CR5","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boque C, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol"},{"key":"2517_CR6","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s12185-017-2208-2","volume":"105","author":"H Nakamae","year":"2017","unstructured":"Nakamae H, Fujisawa S, Ogura M, Uchida T, Onishi Y, Taniwaki M, et al. Dasatinib versus imatinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia: a subanalysis of the DASISION 5-year final report. Int J Hematol. 2017;105:792\u2013804.","journal-title":"Int J Hematol"},{"key":"2517_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12185-017-2353-7","volume":"107","author":"H Nakamae","year":"2018","unstructured":"Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol. 2018;107:327\u201336.","journal-title":"Int J Hematol"},{"key":"2517_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000481945","volume":"94","author":"T Takaku","year":"2018","unstructured":"Takaku T, Iriyama N, Mitsumori T, Sato E, Gotoh A, Kirito K, et al. Clinical efficacy and safety of first-line dasatinib therapy and the relevance of velocity of BCR-ABL1 transcript decline for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia: report from the Juntendo Yamanashi Cooperative Study Group. Oncology. 2018;94:85\u201391.","journal-title":"Oncology"},{"key":"2517_CR9","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"JL Steegmann","year":"2016","unstructured":"Steegmann JL, Baccarani M, Breccia M, Casado LF, Garcia-Gutierrez V, Hochhaus A, et al. European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia. Leukemia. 2016;30:1648\u201371.","journal-title":"Leukemia"},{"key":"2517_CR10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3324\/haematol.13151","volume":"94","author":"DH Kim","year":"2009","unstructured":"Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer\/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135\u20139.","journal-title":"Haematologica"},{"key":"2517_CR11","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1038\/leu.2009.46","volume":"23","author":"S Mustjoki","year":"2009","unstructured":"Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T\/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398\u2013405.","journal-title":"Leukemia"},{"key":"2517_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2009-12-256800","volume":"116","author":"A Kreutzman","year":"2010","unstructured":"Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono\/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772\u201382.","journal-title":"Blood"},{"key":"2517_CR13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12185-013-1483-9","volume":"99","author":"T Kumagai","year":"2014","unstructured":"Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, Takeuchi J, et al. Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol. 2014;99:41\u201352.","journal-title":"Int J Hematol"},{"key":"2517_CR14","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12185-010-0565-1","volume":"91","author":"Y Nagata","year":"2010","unstructured":"Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799\u2013807.","journal-title":"Int J Hematol"},{"key":"2517_CR15","doi-asserted-by":"publisher","first-page":"13283","DOI":"10.1073\/pnas.0702654104","volume":"104","author":"O Hantschel","year":"2007","unstructured":"Hantschel O, Rix U, Schmidt U, Burckstummer T, Kneidinger M, Schutze G, et al. The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci U S A. 2007;104:13283\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2517_CR16","doi-asserted-by":"publisher","first-page":"4055","DOI":"10.1182\/blood-2007-07-102061","volume":"110","author":"U Rix","year":"2007","unstructured":"Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055\u201363.","journal-title":"Blood"},{"key":"2517_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/nbt1328","volume":"25","author":"M Bantscheff","year":"2007","unstructured":"Bantscheff M, Eberhard D, Abraham Y, Bastuck S, Boesche M, Hobson S, et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol. 2007;25:1035\u201344.","journal-title":"Nat Biotechnol"},{"key":"2517_CR18","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1172\/JCI200114005","volume":"108","author":"F Sallusto","year":"2001","unstructured":"Sallusto F, Lanzavecchia A. Exploring pathways for memory T cell generation. J Clin Investig. 2001;108:805\u20136.","journal-title":"J Clin Investig"},{"key":"2517_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1006\/meth.1996.0037","volume":"9","author":"DD Friberg","year":"1996","unstructured":"Friberg DD, Bryant JL, Whiteside TL. Measurements of natural killer (NK) activity and NK-cell quantification. Methods. 1996;9:316\u201326.","journal-title":"Methods"},{"key":"2517_CR20","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/leu.2015.155","volume":"29","author":"H Fujiwara","year":"2015","unstructured":"Fujiwara H, Ochi T, Ochi F, Miyazaki Y, Asai H, Narita M, et al. Antileukemia multifunctionality of CD4(+) T cells genetically engineered by HLA class I-restricted and WT1-specific T-cell receptor gene transfer. Leukemia. 2015;29:2393\u2013401.","journal-title":"Leukemia"},{"key":"2517_CR21","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48:452\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2517_CR22","doi-asserted-by":"publisher","first-page":"8415","DOI":"10.4049\/jimmunol.175.12.8415","volume":"175","author":"BE Palmer","year":"2005","unstructured":"Palmer BE, Blyveis N, Fontenot AP, Wilson CC. Functional and phenotypic characterization of CD57+ CD4+ T cells and their association with HIV-1-induced T cell dysfunction. J Immunol. 2005;175:8415\u201323.","journal-title":"J Immunol"},{"key":"2517_CR23","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1182\/blood-2010-04-281675","volume":"116","author":"NK Bjorkstrom","year":"2010","unstructured":"Bjorkstrom NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood. 2010;116:3853\u201364.","journal-title":"Blood"},{"key":"2517_CR24","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood-2002-07-2103","volume":"101","author":"JM Brenchley","year":"2003","unstructured":"Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood. 2003;101:2711\u201320.","journal-title":"Blood"},{"key":"2517_CR25","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1182\/blood.V79.7.1746.1746","volume":"79","author":"E Legac","year":"1992","unstructured":"Legac E, Autran B, Merle-Beral H, Katlama C, Debre P. CD4+ CD7\u2212 CD57+ T cells: a new T-lymphocyte subset expanded during human immunodeficiency virus infection. Blood. 1992;79:1746\u201353.","journal-title":"Blood"},{"key":"2517_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1383-5769(02)00085-5","volume":"52","author":"H Watanabe","year":"2003","unstructured":"Watanabe H, Weerasinghe A, Miyaji C, Sekikawa H, Toyabe S, Mannor MK, et al. Expansion of unconventional T cells with natural killer markers in malaria patients. Parasitol Int. 2003;52:61\u201370.","journal-title":"Parasitol Int"},{"key":"2517_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1111\/j.1365-2567.2004.01785.x","volume":"111","author":"MC Jimenez-Martinez","year":"2004","unstructured":"Jimenez-Martinez MC, Linares M, Baez R, Montano LF, Martinez-Cairo S, Gorocica P, et al. Intracellular expression of interleukin-4 and interferon-gamma by a Mycobacterium tuberculosis antigen-stimulated CD4+ CD57+ T-cell subpopulation with memory phenotype in tuberculosis patients. Immunology. 2004;111:100\u20136.","journal-title":"Immunology"},{"key":"2517_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/art.10133","volume":"46","author":"T Maeda","year":"2002","unstructured":"Maeda T, Yamada H, Nagamine R, Shuto T, Nakashima Y, Hirata G, et al. Involvement of CD4+,CD57+ T cells in the disease activity of rheumatoid arthritis. Arthritis Rheum. 2002;46:379\u201384.","journal-title":"Arthritis Rheum"},{"key":"2517_CR29","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1182\/blood.V89.8.2822","volume":"89","author":"L Imberti","year":"1997","unstructured":"Imberti L, Sottini A, Signorini S, Gorla R, Primi D. Oligoclonal CD4+ CD57+ T-cell expansions contribute to the imbalanced T-cell receptor repertoire of rheumatoid arthritis patients. Blood. 1997;89:2822\u201332.","journal-title":"Blood"},{"key":"2517_CR30","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1084\/jem.20150792","volume":"212","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Wu N, Lu Y, Davidson D, Colonna M, Veillette A. DNAM-1 controls NK cell activation via an ITT-like motif. J Exp Med. 2015;212:2165\u201382.","journal-title":"J Exp Med"},{"key":"2517_CR31","doi-asserted-by":"publisher","first-page":"358462","DOI":"10.1155\/2015\/358462","volume":"2015","author":"D Oosterhoff","year":"2015","unstructured":"Oosterhoff D, van de Weerd G, van Eikenhorst G, de Gruijl TD, van der Pol LA, Bakker WA. Hematopoietic cancer cell lines can support replication of Sabin poliovirus type 1. Biomed Res Int. 2015;2015:358462.","journal-title":"Biomed Res Int"},{"key":"2517_CR32","first-page":"282","volume":"52","author":"Y Sunami","year":"2011","unstructured":"Sunami Y, Sato E, Ichikawa K, Yasuda H, Komatsu N. Hemorrhagic colitis caused by dasatinib following cytomegalovirus enterocolitis in a patient with chronic myelogenous leukemia in the second chronic phase. Rinsho Ketsueki. 2011;52:282\u20136.","journal-title":"Rinsho Ketsueki"},{"key":"2517_CR33","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/leu.2011.135","volume":"25","author":"A Kreutzman","year":"2011","unstructured":"Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587\u201397.","journal-title":"Leukemia"},{"key":"2517_CR34","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1007\/s12185-012-1132-8","volume":"96","author":"H Tanaka","year":"2012","unstructured":"Tanaka H, Nakashima S, Usuda M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int J Hematol. 2012;96:308\u201319.","journal-title":"Int J Hematol"},{"key":"2517_CR35","doi-asserted-by":"publisher","first-page":"247","DOI":"10.4161\/cbt.27310","volume":"15","author":"ZY Qiu","year":"2014","unstructured":"Qiu ZY, Xu W, Li JY. Large granular lymphocytosis during dasatinib therapy. Cancer Biol Ther. 2014;15:247\u201355.","journal-title":"Cancer Biol Ther"},{"key":"2517_CR36","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.4049\/jimmunol.0800455","volume":"182","author":"J van Bergen","year":"2009","unstructured":"van Bergen J, Kooy-Winkelaar EM, van Dongen H, van Gaalen FA, Thompson A, Huizinga TW, et al. Functional killer Ig-like receptors on human memory CD4+ T cells specific for cytomegalovirus. J Immunol. 2009;182:4175\u201382.","journal-title":"J Immunol"},{"key":"2517_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","volume":"144","author":"F Fei","year":"2009","unstructured":"Fei F, Yu Y, Schmitt A, Rojewski MT, Chen B, Gotz M, et al. Dasatinib inhibits the proliferation and function of CD4+ CD25+ regulatory T cells. Br J Haematol. 2009;144:195\u2013205.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-018-2517-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2517-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T12:15:54Z","timestamp":1659096954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-018-2517-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,27]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["2517"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2517-0","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,27]]},"assertion":[{"value":"25 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest. A summary of relevant information will be published with the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}